Camarda Financial Advisors LLC Invests $286,000 in Johnson & Johnson (NYSE:JNJ)

Camarda Financial Advisors LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJGet Rating) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,674 shares of the company’s stock, valued at approximately $286,000.

Other institutional investors also recently made changes to their positions in the company. Marathon Capital Management grew its holdings in Johnson & Johnson by 4.6% in the 3rd quarter. Marathon Capital Management now owns 27,264 shares of the company’s stock worth $4,404,000 after buying an additional 1,200 shares in the last quarter. Castle Rock Wealth Management LLC grew its holdings in Johnson & Johnson by 3.9% in the 4th quarter. Castle Rock Wealth Management LLC now owns 12,855 shares of the company’s stock worth $2,119,000 after buying an additional 479 shares in the last quarter. Blueshift Asset Management LLC grew its holdings in Johnson & Johnson by 671.9% in the 3rd quarter. Blueshift Asset Management LLC now owns 30,365 shares of the company’s stock worth $4,904,000 after buying an additional 26,431 shares in the last quarter. Pallas Capital Advisors LLC grew its holdings in Johnson & Johnson by 42.1% in the 3rd quarter. Pallas Capital Advisors LLC now owns 68,839 shares of the company’s stock worth $11,363,000 after buying an additional 20,404 shares in the last quarter. Finally, Greytown Advisors Inc. boosted its stake in Johnson & Johnson by 13.6% during the 3rd quarter. Greytown Advisors Inc. now owns 8,726 shares of the company’s stock valued at $1,409,000 after purchasing an additional 1,045 shares in the last quarter. Institutional investors and hedge funds own 68.78% of the company’s stock.

JNJ opened at $176.98 on Friday. The firm has a market cap of $465.71 billion, a PE ratio of 23.85, a P/E/G ratio of 2.87 and a beta of 0.66. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. The business has a fifty day simple moving average of $178.61 and a 200-day simple moving average of $170.89. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.60 by $0.07. The company had revenue of $23.43 billion during the quarter, compared to analyst estimates of $23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.59 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post 10.2 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th will be issued a $1.13 dividend. The ex-dividend date of this dividend is Monday, May 23rd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.55%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s dividend payout ratio is presently 57.14%.

In related news, VP Thibaut Mongon sold 23,681 shares of the stock in a transaction on Thursday, March 17th. The stock was sold at an average price of $176.25, for a total transaction of $4,173,776.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider William Hait sold 29,699 shares of the stock in a transaction on Thursday, April 21st. The stock was sold at an average price of $183.58, for a total value of $5,452,142.42. Following the sale, the insider now owns 80,236 shares of the company’s stock, valued at $14,729,724.88. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.

A number of equities analysts have issued reports on JNJ shares. Citigroup decreased their price target on Johnson & Johnson from $210.00 to $205.00 in a research note on Tuesday, May 17th. Raymond James increased their price target on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Bank of America started coverage on Johnson & Johnson in a research note on Wednesday, March 2nd. They set a “neutral” rating for the company. The Goldman Sachs Group increased their price target on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Finally, Sanford C. Bernstein lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and raised their price objective for the stock from $180.00 to $183.00 in a research note on Wednesday, March 16th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $187.86.

Johnson & Johnson Company Profile (Get Rating)

Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.